Emergent BioSolutions Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2003
Net Income	-565.2	-760.5	-211.6	219.5	305.8	54.5	Upgrade
Depreciation & Amortization	118.4	125.1	143.3	123.8	114.5	110.7	Upgrade
Share-Based Compensation	22.2	23.1	45.1	42.4	51.8	26.7	Upgrade
Other Operating Activities	339.7	406	-10.9	-65.5	64.8	-3.9	Upgrade
Operating Cash Flow	-84.9	-206.3	-34.1	320.2	536.9	188	Upgrade
Operating Cash Flow Growth	-	-	-	-40.36%	185.59%	349.76%	Upgrade
Capital Expenditures	-47.3	-51.6	-115.8	-224.1	-141.9	-86.9	Upgrade
Acquisitions	263.9	263.9	-243.7	0	-10	-10	Upgrade
Other Investing Activities	-	-	-21.8	-	-	-	Upgrade
Investing Cash Flow	216.6	212.3	-381.3	-224.1	-151.9	-96.9	Upgrade
Share Issuance / Repurchase	10.2	10.2	-77.1	-90.1	31.6	8.2	Upgrade
Debt Issued / Paid	-493.9	-543.4	564.2	-35.9	54.5	13.7	Upgrade
Other Financing Activities	-0.8	-2.5	-5.9	-15	-16.6	-57.8	Upgrade
Financing Cash Flow	-484.5	-535.7	481.2	-141	69.5	-35.9	Upgrade
Exchange Rate Effect	-1	-1.2	0.5	-0.3	-1	0.4	Upgrade
Net Cash Flow	-353.8	-530.9	66.3	-45.2	453.5	55.6	Upgrade
Free Cash Flow	-132.2	-257.9	-149.9	96.1	395	101.1	Upgrade
Free Cash Flow Growth	-	-	-	-75.67%	290.70%	-	Upgrade
Free Cash Flow Margin	-11.15%	-24.58%	-13.41%	5.42%	25.04%	9.14%	Upgrade
Free Cash Flow Per Share	-2.53	-5.04	-2.99	1.80	7.50	1.96	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).